Silo Pharma Inc (SILO)

[Awl416]

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

[Awl416]

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic

[Monksdream]

SILO 10Q due 3/26
Next day settlement 5/28 per SEC mandate

[Monksdream]

SILO under $2

[Monksdream]

SILO under $2

[Michael TRed]

Low floater. Could see 5$ quick

[Michael TRed]

2$ +

[Michael TRed]

Load

[Monksdream]

SILO

[subslover]

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
Study data to determine potential delivery partners

ENGLEWOOD CLIFFS, NJ, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD, and other stress related disorders. The formulation development was in accordance with the Company’s sponsored research agreement and option with Columbia University. Linearity, accuracy, and repeatability were achieved in the feasibility study.

“The progress of our feasibility study investigating dose strengths of SPC-15 is a significant advancement in our development work with this pipeline candidate,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Results of the feasibility study will determine our selection of the manufacturing processes, and we are currently in discussions with potential delivery partners. We may also use the feasibility data for upcoming studies related to our SPC-14 therapeutic targeting Alzheimer’s disease.”

In May 2023, Silo Pharma was awarded a U.S. Patent titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,” with claims protecting the key technology behind SPC-15 and further drug discovery.

About Silo Pharma

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com

[MasterBlastr]

Looks the the garbage squad got a hold of this . . .

[Awl416]

Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic

[Garbage2Gucci]

$SILO gaining traction on news #PTSD #Anxiety

Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
https://finance.yahoo.com/news/silo-pharma-commences-formulation-spc-130000596.html

Data to Support Alzheimer’s Study

ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD.

Development of the drug formulation is pursuant to the Company’s sponsored research agreement with Columbia University. Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders.

“We are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The SPC-15 treatment protocol predicts levels of severity or progression of stress-related disorders and their metabolomic biomarkers’ response to pharmacological treatments. Based on our own research to date coupled with published preclinical data, we believe SPC-15 could have a profound impact on treating stress and anxiety disorders including PTSD, we will further use this data to help us with our upcoming studies related to SPC-14 Alzheimer’s asset.”

Targeted by SPC-15, anxiety, PTSD, and other stress-related disorders are becoming more frequent in Americans aged 18+. According to the World Health Organization in 2019, 300+ million people were living with an anxiety disorder, and according to the National Center for PTSD, around 12 million adults in the U.S. alone are reported to have PTSD., According to Fortune Business Insights, the global treatment market size for anxiety disorders and depression is projected to reach $13.0 billion in 2027.

Silo Pharma was recently granted a U.S. patent covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females.

About Silo Pharma

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit www.silopharma.com

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

Contact
800-705-0120
[e-mail]

World Health Organization; Mental disorders. June 2022.
U.S. Department of Veterans Affairs, PTSD: National Center for PTSD; How Common Is PTSD in Adults?

[TheFinalCD]

SILO NEWS TODAY POPS TO 2.50 DROPS TO 1.75



https://finviz.com/quote.ashx?t=SILO&ty=c&ta=1&p=d

[glenn1919]

SILO.............................https://finviz.com/quote.ashx?t=SILO&ty=c&ta=1&p=d

[TheFinalCD]

https://finviz.com/quote.ashx?t=SILO&ty=c&ta=1&p=d

[glenn1919]

SILO..................................https://stockcharts.com/h-sc/ui?s=SILO&p=W&b=5&g=0&id=p86431144783

[tw0122]

Let’s go share buyback 1 million shares

[Awl416]

News

[Laster]

Really hope people listened and actually read the news.

[IVANj]

Lots of vol…. Took 3.15 for a bounce

[Invest-in-America]

FUNNY!!!

[Invest-in-America]

Was just joking, Dude!! (I fully GET all of your reply there, & THANKS!!)

[Laster]

Animal data is no real news.
Stock should drift back and close the gap eventually.
Definitely not a runner on THAT news.
JMO.

[KOmani]

I mean the reason the price broke down was shorting.

Whether those shorts have non-public information is what makes it scummy.

[Laster]

Typical trader response. No clue about how biotechs work.
This animal study announced is just a pump.
Only if I could short a stock. This would have been the one when it was over $6.
Sorry BRO!!!!

[Invest-in-America]

SILO: Heck, that all "Humans" are too, Bro!!!

[Laster]

Just an animal study.
OMG.
This run will be very short lived.
JMO.

[tw0122]

6.91 Silo Pharma shares are trading higher after the company announced study results of SPU-21 for arthritis. The company said SPU-21 is effective in controlling arthritis

[tw0122]

Up 50% nice

[Jaydixson1]

Is this a good one

[Pirateshipatbay]

This looks like buys are coming in here 5.25

[subslover]

R/S are hot? I must have eaten the wrong mushrooms like the ancient Greeks!

[Renee]

SILO moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

SILO: one for 50 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[PennyMaster]

$SILO Nice News out!! Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR
Brett Maas
646-536-7331
Email: [e-mail]

https://finance.yahoo.com/news/silo-pharma-announces-positive-results-121500306.html

[subslover]

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
Press Release | 07/27/2022
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

[R4000]

Wonder how/if the uplist to the Nas is going... either way I think there is a lot of upside here imo.

[jfk]

'Big runner' is down significantly, and not moving/playing dead. What's going to change that?

[StockHighAlert-]

$SILO We have a big runner setting up here.

[Louied91]

$SILO Silo Pharma Advances Psychedelic Patent Portfolio


https://www.globenewswire.com/news-release/2021/08/25/2286293/0/en/Silo-Pharma-Advances-Psychedelic-Patent-Portfolio.html

Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.

“Each of these PCT applications relates to the continued research and development that Silo Pharma has continued to undertake.” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are excited to have taken this important next step to protect our intellectual property.”

These three PCT applications title listed below along with Silo Pharma’s granted IP expands the potential addressable patient population that needs unique patient-focused therapeutics.

CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN

CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN

The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications.

[StockHighAlert-]

#BreakingNews: $SILO Silo Pharma Advances #Psychedelic Patent Portfolio @TENAssociates https://yhoo.it/2WlSbM6

[StockHighAlert-]

$SILO 8k report released https://t.co/LnGKLX6h3F @TENAssociates

[StockHighAlert-]

$SILO #SiloPharma Secures #Patent that May be Used for #Psychedelics Delivery #Technology @TENAssociates https://www.cannabisfn.com/silo-pharma-secures-patent-that-may-be-used-for-psychedelics-delivery-technology/

[StockHighAlert-]

$Silo Pharma Stock Vs. $Silo Wellness Stock: What’s the Difference? @TENAssociates https://cnafinance.com/silo-pharma-stock-vs-silo-wellness-stock-whats-the-difference/

[StockHighAlert-]

$SILO Keep on radar more news/updates coming soon.. @TENAssociates https://yhoo.it/37zvyGa

[StockHighAlert-]

$Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research https://finance.yahoo.com/news/silo-pharma-announces-jv-partner-121000941.html

[Louied91]

$SILO Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

https://www.globenewswire.com/news-release/2021/08/11/2278771/0/en/Silo-Pharma-Announces-that-JV-partner-Zylo-Therapeutics-Successfully-Completes-Initial-Inspection-for-Ketamine-Intradermal-Research.html

Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control.

Eric Weisblum, CEO of Silo Pharma stated “Completion of the first inspection is an important step forward in our goal to develop a transdermal Ketamine therapeutic with the patented Z-Pod® technology. The potential ability to deliver Ketamine or Psilocybin in a time-released and dosage controlled manner would be ground-breaking and we intend to continue exploring this exciting opportunity.”

[StockHighAlert-]

$SILO Silo Pharma presents at Proactive's One2One virtual investor forum @TENAssociates

[StockHighAlert-]

$SILO Load more while you can! Hearing News dropping any day now! @TENAssociates